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In recent years there have been major advances with respect to the
identification of the protein components andmechanisms of micro-
RNA (miRNA) mediated silencing. However, the complete and pre-
cise repertoire of components and mechanism(s) of action remain
to be fully elucidated. Herein we reveal the identification of a
family of three LIM domain-containing proteins, LIMD1, Ajuba
and WTIP (Ajuba LIM proteins) as novel mammalian processing
body (P-body) components, which highlight a novel mechanism
of miRNA-mediated gene silencing. Furthermore, we reveal that
LIMD1, Ajuba, and WTIP bind to Ago1∕2, RCK, Dcp2, and eIF4E
in vivo, that they are required for miRNA-mediated, but not
siRNA-mediated gene silencing and that all three proteins bind
to the mRNA 5′ m7GTP cap–protein complex. Mechanistically, we
propose the Ajuba LIM proteins interact with the m7GTP cap struc-
ture via a specific interaction with eIF4E that prevents 4EBP1 and
eIF4G interaction. In addition, these LIM-domain proteins facilitate
miRNA-mediated gene silencing by acting as an essential molecular
link between the translationally inhibited eIF4E-m7GTP-50cap and
Ago1∕2 within the miRISC complex attached to the 3′-UTR of
mRNA, creating an inhibitory closed-loop complex.
argonaute ∣ eIF4E ∣ tumor suppressor ∣ P-bodies ∣ m7GTP cap
MicroRNAs (miRNAs) are small noncoding RNAs that playimportant roles in a wide range of biological processes in-
cluding development, cellular differentiation, proliferation,
apoptosis, and cancer (1). To execute their regulatory functions
miRNAs assemble together with the Argonaute (Ago) proteins
into miRNA induced silencing complexes (miRISCs) (2). miR-
NAs within these complexes guide the bound Ago proteins to
fully or partially complementary mRNA target sequences, result-
ing in mRNAs that are then silenced posttranscriptionally (2).
Despite major advances in identifying key components of this
pathway the complete protein repertoire and mechanism(s) of
miRNA-mediated silencing remain to be fully elucidated. Here
we show a distinct mechanism of miRNA-mediated silencing
through the identification of three unique mammalian processing
body (P-body) associated proteins, LIMD1, Ajuba, and WTIP
(Ajuba LIM proteins) (3). The Ajuba LIM proteins are part
of the larger Zyxin family, characterized by triple tandem arrayed
c-terminal zinc-finger LIM domains. We demonstrate that these
three LIM-domain containing proteins (4) interact with compo-
nents of RNA induced silencing complexes (RISC) as well as
eIF4E and the mRNA m7GTP cap–protein complex and are re-
quired for miRNA-mediated gene silencing. We propose a model
whereby the LIMD1, Ajuba, and WTIP proteins enable miRNA-
mediated silencing by facilitating a simultaneous association
between the translationally repressed m7GTP cap structure
and an active miRISC complex attached to the 3′-UTR of
mRNA. We propose this role in miRNA-mediated regulation re-
presents a tumor suppressive function of Ajuba LIM proteins,
specifically LIMD1, which has previously been validated as a
bona fide tumor suppressor in lung cancer. This function is in
keeping with current evidence implicating the disruption of the
miRNA pathway with cancer initiation and development (5).
Results and Discussion
LIMD1 Is a Component of Cytoplasmic P-bodies. LIMD1 and its fa-
mily members have been shown to localize to sites of cell adhe-
sion where their activity regulates cell–cell adhesion, migration,
and intracellular signaling via a nucleo-cytoplasmic shuttling
function (4, 6). However, there is a cytoplasmic reservoir of
LIMD1 not associated with the cytoskeleton the function of
which is unclear (7). We performed a series of experiments to
characterize the localization and thus infer possible functions of
cytoplasmic LIMD1. Enhanced green fluorescent protein-tagged
(EGFP) LIMD1 was expressed in U2OS cells and we observed a
variety of subcellular localization patterns (Fig. S1). Of specific
interest was the presence of discrete cytoplasmic foci, a pattern
that showed remarkable similarity to that described for mamma-
lian P-bodies. P-bodies are currently believed to form as a con-
sequence of miRNA-mediated silencing and are sites where re-
pressed mRNAs accumulate and are subject to degradation or
storage (3, 8, 9). P-bodies are identified by the composition of
proteins that function in cap-dependent translation (eIF4E),
translation suppression (RCK), RNA interference-mediated
posttranscriptional gene silencing (Ago2, GW182), and decap-
ping of mRNA (Dcp2) (10–12). To determine if these LIMD1
associated cytoplasmic foci also contain P-body associated pro-
teins, YFP-tagged Ago2, RCK/p54, Dcp2, and eIF4E were
coexpressed in U2OS cells with mTangerine-tagged LIMD1
(mTan-LIMD1) (Fig. 1 A and B). We observed colocalization
between mTan-LIMD1 and YFP-eIF4E and YFP-Dcp2 and to
a lesser extent (but still significant) between mTan-LIMD1 and
YFP-RCK/p54 and YFP-Ago2 (Fig. 1 A and B). The quantified
colocalization coefficient values confirmed the degree of
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colocalization visualized for the mTan-LIMD1 and YFP-P-body
component pairs (Fig. S2).
GW182 is reported to be required for P-body formation and in
conjunction with Ago2 essential for miRNA-mediated gene silen-
cing (13). We therefore, performed additional colocalization
studies to visualize endogenous human GW182 with mTan-
LIMD1 and other YFP-tagged P-body components Ago2, RCK,
Dcp2, and eIF4E. As expected we observed localization of the
know RISC protein components into P-body structures (Fig. 1C)
(13). Notably, we also found specific colocalization of endogen-
ous LIMD1 and GW182 (Fig. 1 D–F). Interestingly, both endo-
genous LIMD1 and GW182 formed smaller P-body structures in
U2OS cells (approximately 5–10 nm) (Fig. 1F) compared to the
range in size of P-bodies (100–300 nm) detected upon ectopic
expression of YFP-Ago2/eIF4E and EGFP-LIMD1 (Fig. 1C).
LIMD1 Interacts with RISC and the m7GTP Cap Complex. To further
investigate whether LIMD1 interacted with components of RISC
Xpress-tagged LIMD1 was coexpressed with YFP-tagged Ago2,
RCK, Dcp2, and eIF4E in U2OS cells and the protein complexes
immunoprecipitated (IP). Western blotting of the immunopuri-
fied complexes revealed that Ago2, RCK, Dcp2, and eIF4E
formed complexes with LIMD1 (Fig. S3A). To determine whether
these were protein–protein interactions or via an RNA compo-
nent, we also performed the IP in the presence of RNase A. In-
teraction of LIMD1 with Ago1, Ago2, and eIF4E was insensitive
to RNase A, in contrast RCK and Dcp2 were found to be partially
and significantly dependent upon RNA, respectively (Fig. 1G). To
map the binding interface we used GST fusion proteins of full-
length LIMD1, the pre-LIM region (GST-Δ472–676) and LIM
domains (GST-Δ1–467) and incubated these with U2OS cell
extracts transfected with either HA-tagged Ago1, Ago2, YFP-
tagged RCK, Dcp2, or eIF4e. Fig. S3B shows that all of these
proteins interacted with full-length LIMD1. Ago1, Ago2, and
eIF4E bound to the pre-LIM region, whereas the RNA-mediated
interaction of RCK/p54 and Dcp2 were dependent on the context
of full-length LIMD1. None of the proteins tested were able to
interact with the LIM domains (Fig. S3B). To confirm the validity
and biological significance of the above interaction in vivo we
showed that endogenous LIMD1 coimmunopurified endogenous
Ago2 from U2OS cells extracts (Fig. 1H).
LIMD1 Directs P-body Assembly. To determine whether LIMD1 was
essential for P-body formation and integrity we depleted endo-
genous LIMD1 from U2OS cells using lentiviral shRNA-
mediated RNAi and examined the effects on P-body formation.
We developed U2OS cell lines that stably express scrambled
shRNA (negative control), a LIMD1-5′UTR targeted shRNA
(sh-LIMD1 5′) and a LIMD1-targeted shRNA, allowing concur-
rent expression of an RNAi resistant Flag-His-tagged LIMD1
wild-type protein (rrΔLIMD1-FL) or a LIM domains deletion
mutant protein (rrΔ472–676) (Fig. 2A). Cells were transiently
transfected with each of the four indicated YFP-P-body markers
Ago2, RCK, Dcp2, and eIF4E. For all four markers in the
scrambled shRNA cells we detected the characteristic P-body pat-
tern and distribution (Fig. 2B, first column). Loss of LIMD1 ex-
pression (sh-LIMD1-5′) resulted in a significant decrease in the
number of eIF4E or Dcp2 associated P-bodies (Fig. 2B, second
column), indicating that endogenous LIMD1 is required for a
specific subset of eIF4E/Dcp2 (but not Ago2/RCK) enriched
P-bodies. Rescued-expression of wild-type LIMD1 (rr-LIMD1
FL) resulted in the reformation of eIF4E and Dcp2 P-bodies
Fig. 1. In vivo colocalization and binding of LIMD1 to eIF4E, Dcp2, Ago2, and RCK within P-bodies. (A) U2OS cells transiently cotransfected to express mTAN-
LIMD1 and the indicated YFP-tagged P-body proteins, were fixed 48 h posttransfection and proteins visualized by confocal microscopy. (B) Digital zoom show-
ing greater detail of the degree of colocalization for the indicated merged panels. (C) Endogenous LIMD1 and GW182 colocalize in U2OS cells. U2OS cells were
cotransfected with mTan-LIMD1 and the indicated EYFP-P-body marker proteins. At 48 h posttransfection, cells were fixed and then immunocytochemistry
performed using anti-GW182 (human serum #18033). Triple colocalization is indicated by white coloration in merged panel. Scale bar ¼ 10 μm. (D) U2OS cells
were fixed and then immunocytochemistry performed using anti-LIMD1 (monoclonal 3F2/C6) and anti-GW182 (human serum #18033 ) to detect endogenous
proteins. Scale bar ¼ 10 μm. (E) Higher magnification of boxed region in (D), Scale bar ¼ 5 μm and (F) digital zoom of boxed region in (E) to highlight
colocalized (yellow) LIMD1/GW182 positive foci/P-bodies (white arrows). (G) Extracts derived from U2OS cells expressing Xpress®-tagged LIMD1 together with
the indicated YFP-tagged proteins, were incubated in the absence or presence of RNAse A and proteins recovered by immunoprecipitation with anti-GFP
antibodies. (H) Endogenous coprecipitation of Ago2 with LIMD1. 2.5 μg of anti-LIMD1 (monoclonal 3F2/C6) or isotype specific controls were used for immu-
noprecipitation. Proteins detected by Western blotting with anti-Ago2 (C34C6) antibody and antimouse IgG shown as input control.






















to the level observed in the scrambled shRNA control cell line
(Fig. 2B, compare first and third column; quantified in Fig. 2C).
In contrast, reexpression of the LIMD1 deletion mutant (rrΔ472–
676-FL) did not reverse this effect (Fig. 2B, rightmost column).
These findings demonstrated a critical function for full-length
LIMD1 in the formation of P-bodies, specifically those rich in
Dcp2 and eIF4E. Furthermore, the three terminal LIM domains
are likely to be integral to this function. In light of the above
findings we postulated that LIMD1 might be a key regulatory
component of miRNA-mediated gene silencing.
LIMD1 Is a Critical Component of miRNA-Mediated Silencing. The ma-
jority of proteins critical for miRNA silencing localize to P-bodies
(13–15) and their depletion often results in disruption of P-body
formation as well as loss of miRNA-mediated silencing (14–16).
The loss of ability for eIF4E and Dcp2 to localize to P-bodies
following LIMD1 depletion (Fig. 2) suggests LIMD1 may have
an early association with miRISC/mRNP silenced complexes
and a function therein (10, 17). Furthermore, the predominant
disruption of eIF4E/Dcp2 containing P-bodies but not Ago2/
RCK-bodies by LIMD1 depletion is also suggestive of LIMD1
being preferentially involved in the translational initiation and
decapping mechanism of miRNA silencing rather than the siR-
NA-mediated process that requires Ago2 and RCK (16, 18).
We utilized the shRNA-directed knockdown and rescue cell
lines to determine whether LIMD1 functions as a critical effector
protein that specifically enables miRNA-mediated gene silencing.
Cell lines were transfected with Ren/Luc reporters containing
complementary and partially complementary Let-7a sites to dis-
tinguish between siRNA and miRNA-mediated silencing. In
agreement with our hypothesis, stable depletion of LIMD1
caused a specific derepression of miRNA but not siRNA-
mediated silencing (Fig. 3A). Furthermore, this effect could be
reversed in the rrLIMD1-FL knockdown/rescue cell line where
an RNAi-resistant wild-type LIMD1 was expressed simulta-
neously with depletion of the endogenous protein (Fig. 3A).
Rescue with the LIMD1Δ472–676 deletion mutant was unable
to reverse the derepressive effect (Fig. 3A). To further corrobo-
rate the role of LIMD1 in miRNA-mediated silencing we
repeated the reporter assay using wild-type and Limd1−∕− null
mouse embryonic fibroblasts (MEFs) (19). These data confirmed
that loss of LIMD1 expression results in a specific loss of miRNA-
mediated silencing (Fig. 3B). We therefore hypothesized that dis-
ruption of LIMD1 expression and therefore miRNA-mediated
silencing, could be one of the mechanisms by which LIMD1 con-
tributes to cellular transformation and tumorigenesis, in keeping
with the role of miRNA-mediated gene silencing as a tumor sup-
pressive regulatory pathway (5, 20–22). The specific loss of miR-
NA-mediated silencing in LIMD1−∕− MEFs supports a link
between the disruption of this pathway and the protumorigenic
phenotype reported in these mice (19). This theory was further
supported by the findings that LIMD1−∕− MEFs had translation
rates significantly higher (40%) than wild-type MEFs as deter-
mined by [35S]-methionine incorporation assays (Fig. 3C).
Ectopic expression of LIMD1 that increased P-body numbers
and size (Fig. 1) also enhanced Let-7a specific miRNA-mediated
silencing (Fig. S4). This is in agreement with published data
where increased P-bodies represent more repressed mRNA mul-
timerized into a P-body (3). The finding that LIMD1 represents a
critical component of the miRNA silencing pathway prompted us
to compare the ability of LIMD1 to specifically regulate miRNA
silencing with other validated proteins implicated in RNAi. To
this end we employed siRNA-targeted knockdown of Ago1,
Ago2, RCK/p54, GW182, Dcp2, and eIF4E in addition to LIMD1
and compared the levels of specific siRNA and miRNA-mediated
repression (Fig. 3D). In corroboration with our previous data,
siRNA-targeted depletion of LIMD1 caused an attenuation of
miRNA-mediated silencing (Fig. 3D). This was similar to that ob-
served with ablation of GW182. In comparison, loss of Ago2 re-
sulted in a specific derepression of siRNA-mediated silencing
(Fig. 3D). The degree of siRNA-targeted depletion for each of
the indicated RNAi components and LIMD1 were confirmed
via qRT-PCR (Fig. S5A). Quantification of luciferase mRNA
by qRT-PCR showed that at least for Let-7a targets, loss of
LIMD1 did not affect reporter mRNA levels (Fig. S5B). This im-
plies that LIMD1 exerts its physiological effects during miRNA
silencing at the level of translation inhibition and not at the level
of mRNA half-life or rates of degradation.
To determine if LIMD1-regulated silencing occurs with an en-
dogenous 3′UTR Let-7 target sequence we utilized a pMIR-CMV
luciferase reporter fused to the full-length 3′UTR of High Mo-
bility Group AT Hook 2 (HMGA2) (23). Depletion of LIMD1 by
targeting siRNA resulted in a derepression of silencing similar to
that seen previously (Fig. S6A). The use of 2′OMe inhibitors
against Let-7a demonstrated these reporters were regulated via
Fig. 2. Depletion of endogenous LIMD1 decreases P-body number. U2OS
cells were transduced with lentivirus to stably express scrambled shRNA (a
negative control), LIMD1-5′-UTR targeted shRNA (sh-LIMD1 (5′) shRNA) or
a LIMD1 targeted shRNA, with concurrent expression of an RNAi resistant
Flag-His-tagged LIMD1 protein (LIMD1-FL). (A) Stable knockdown of endo-
genous LIMD1 and expression of the RNAi resistant protein, LIMD1-FL
confirmed by Western blotting. The band at approximately 75 kDa in the
rrΔ472–676 lane represents residual endogenous LIMD1. (B) YFP fused
P-body protein markers were overexpressed in these cell lines and visualized
by confocal microscopy. (C) P-body numbers were quantified for all cells in
the field of view (×63 magnification) and data from at least 3 random fields
were collected and analyzed using Prism 4 software.





























Let-7 in agreement with published studies (23) and the derepres-
sive effect was equivalent to that observed after depletion of
LIMD1 (Fig. S6A). Interestingly, when we combined LIMD1 de-
pletion with inhibition of Let-7 we did not observe any additional
enhancement of luciferase expression (Fig. S6A). Therefore, in-
dicating LIMD1 activity is unlikely to be via a pathway that is
independent of Let-7 mediated silencing. The degree of LIMD1
knockdown was confirmed via qRT-PCR (Fig. S6B). To confirm
these findings we extracted protein from U2OS cells targeted
with siRNA against LIMD1 or 2′OMe inhibitors of Let-7.
The extent of LIMD1 depletion was quantified by qRT-PCR
(Fig. S6E). Western blotting of endogenous HMGA2 demon-
strated an increase in protein level after inhibition of Let-7 or
depletion of LIMD1 (Fig. S6C). Analysis of HMGA2 mRNA
by qRT-PCR showed no significant changes in mRNA levels
(Fig. S6D) indicating the increase in HMGA2 protein is likely
dependent on release of translational repression.
Ajuba and WTIP Associate with LIMD1 in P-bodies and Have A Critical
Role in miRNA-Mediated Silencing. The six Zyxin family members
can be divided into two subgroups based on a phylogenetic rela-
tionship at the genetic level (Fig. 4A). We therefore examined the
possibility of whether the closely related subgroup members
Ajuba and WTIP, also associate with LIMD1 into P-bodies and
whether they too play a role in miRNA-mediated gene silencing.
U2OS cells transfected with vectors expressing Asred-tagged-
LIMD1 and EGFP-tagged Ajuba, LIMD1, or WTIP showed a
high degree of colocalization (Fig. 4 B and C). In contrast, there
was little colocalization of LIMD1 with TRIP6, LPP, or Zyxin
(Fig. 4 B and C). Because we had established the LIMD1 cyto-
plasmic foci to be P-bodies these data indirectly suggest that like
LIMD1, Ajuba, and WTIP also represented unique components
of P-bodies. Ajuba and WTIP were also found to immunopreci-
pitate with P-body components Ago1, Ago2, RCK, Dcp2, or
eIF4E in vivo (Fig. S7). We next determined if the association of
Ajuba andWTIP with P-bodies was an indication of a specific role
in miRNA gene silencing. siRNA-targeted depletion of all six
Zyxin family members was compared with depletion of Ago2
and GW182. Fig. 4D shows that like LIMD1, depletion of Ajuba
or WTIP had similar specific derepressive affects on miRNA-
mediated silencing. However, the more distantly related family
member proteins Zyxin, Trip6, and LPP had no significant effects
on either miRNA or siRNA-mediated silencing (Fig. 4D). There-
fore, these data establish LIMD1, Ajuba, and WTIP as a unique
family of P-body associated components required for miRNA-
mediated silencing. The degree of siRNA-targeted depletion for
each of the indicated RNAi-mediated silencing components and
Ajuba LIM protein family were confirmed via qRT-PCR (Fig. S8).
Relative expression of LIMD1, Ajuba, and WTIP in U2OS and
HEK293 cell lines was determined by Western blot (Fig. S9A).
LAW Proteins Interact with the m7GTP Cap Complex. The precise
mechanism of mammalian miRNA-mediated silencing of gene
expression is still under debate with one fundamental issue being
whether repression occurs at translation initiation or postinitia-
tion (3, 24). However, there is growing evidence favoring an in-
teraction between the 50-m7GTP cap structure and the 3′UTR
bound Ago2/GW182 miRISC complex, facilitating inhibition of
either translation initiation or elongation (25, 26). For human
Let-7a, the ability to inhibit translation initiation of target mRNA
is dependent on the presence of an m7GTP cap structure (27). We
therefore reasoned that due to the ability of LIMD1 to bind
eIF4E and regulate endogenous Let-7a-mediated silencing,
LIMD1, Ajuba, and WTIP proteins might function in miRNA
silencing by simultaneously binding eIF4E and/or m7GTP cap
and the miRISC complex in a possible inhibitory mRNA closed-
loop complex. To examine this, we investigated the association of
Xpress-tagged Zyxin family proteins with the m7GTP cap. Fig. 5A
shows that LIMD1, Ajuba, and WTIP could be specifically
copurified from U2OS cell extracts with endogenous eIF4E using
m7GTP-Sepharose but not control GTP-Sepharose beads
(Fig. 5A), whereas the less related subgroup Zyxin, LPP, and
Trip6 were not (Fig. 5B). The interactions between LIMD1, Aju-
ba, and WTIP proteins and m7GTP-sepharose could be inhi-
bited by addition of the inhibitory cap-analog, m7GpppG
(Fig. 5A), but were not affected by RNase A treatment (Fig. 5B).
To further dissect out how LIMD1 binding at the m7GTP cap
might function to prevent translation initiation we performed fur-
ther binding studies with GST-eIF4E, GST-LIMD1, and GST-
LIMD1 deletion mutants. These experiments (Fig. 5C) revealed
Fig. 3. LIMD1 is specifically involved in miRNA-mediated gene silencing. Release of gene repression by siRNA or miRNA-targeted events are presented as fold
induction of RL over FFL (see Methods for details). (A) Depletion of endogenous LIMD1 derepresses miRNA-mediated gene silencing. The stable cell lines
described in Fig. 2 expressing scrambled, sh-LIMD1-5′, rrLIMD1-FL or rrΔ472–676-FL were transfected with the si-Let7 and mi-Let7 RL/FFL reporters. After
24 h, total cell extracts were analyzed for dual-luciferase activity. and changes in relative luciferase activities presented as fold induction of RL over FFL
(see Methods for details). (B) miRNA-mediated gene silencing in Limd1−∕− mouse embryonic fibroblasts (MEFs). si-Let7 and mi-Let7a-pSiCheck reporters were
transfected into wild-type and Limd1−∕− derivedMEFs. After 24 h luciferase activities determined, as described. (C) Rates of protein synthesis for wild-type MEF
and LIMD1 null−∕− MEFs were determined via 35S-Met incorporation assay. Values shown as % of wild type control set to 100%. (D) U2OS cells were transfected
with the indicated siRNAs. At 48 h posttransfection, cells were further transfected with si-Let7 and mi-Let7 RL/FFL luciferase reporters; following a further 24 h
cell extracts were assayed for luciferase activity as described above.






















that GST-LIMD1 bound endogenous eIF4E, eIF4A, and PABP
but not 4EBP1 or eIF4G, whereas GST-eIF4E bound LIMD1,
eIF4A, 4EBP1, eIF4G, and PABP (Fig. 5C). This suggests
LIMD1 may act in a similar manner to eIF4G by binding eIF4E,
4A, and PABP, but with the additional ability of interacting with
the translationally inhibitory miRISC via direct and indirect in-
teractions with Ago1∕2, and RCK/DCP2 respectively. Further-
more, the consistent binding of eIF4A suggests this initiation
factor might play a role in miRNA-mediated translational repres-
sion together with LIMD1.
LIMD1 Enhances the Association of eIF4E and Ago2. We next sought
evidence to show that LIMD1 could simultaneous interact with
miRISC and the eIF4E∕m7GTP cap complex to form/stabilize a
possible translationally inhibited closed-loop complex. U2OS
cells were transfected with Xpress-LIMD1, EYFP-eIF4E, and
HA-Ago2 (representative of miRISC) (Fig. 5D). These experi-
ments showed an increase in the coimmunoprecipitation of
Ago2 with eIF4E upon the additional coexpression of LIMD1
(Fig. 5D, arrow).
In summary, we have demonstrated that LIMD1, Ajuba, and
WTIP localize to P-bodies and that LIMD1 is a required compo-
nent for the formation of foci that are rich in eIF4E and Dcp2 and
may represent a distinct subset of P-bodies where mRNA is pro-
cessed in a specific manner not requiring the constant presence of
Ago2 and RCK. Like other components of P-bodies, LIMD1,
Ajuba, and WTIP also function in miRNA-mediated silencing
and thus represent a unique family of essential proteins involved
in this pathway. LIMD1 interacts with several miRISC compo-
nents as well as factors of the translation initiation complex in-
cluding eIF4E, facilitating the interaction between Ago2 and
eIF4E. This supports a model where by LIMD1 acts in a role si-
milar to eIF4G, binding eIF4E-m7GTP cap and other initiation
complex factors (including eIF4A), but with the additional ability
of recruiting the bound miRISC generating a translationally in-
hibitory closed-loop complex thus enabling silencing (proposed
model Fig. S9B).
In conclusion, we propose the involvement of LIMD1 in miR-
NA-mediated silencing is consistent with its tumor suppressive
role and may reflect the protumorigenic phenotype reported in
LIMD1−∕− mice (19). This would be consistent with the enhanced
cellular transformation and tumorigenesis reported when compo-
nents of the miRNA biogenesis pathway are aberrantly expressed
(5, 20–22). To date, tumor suppressor activity associated with
RNAi has been attributed to proteins that regulate miRNA
biogenesis (such as TRBP2, Lin28, and p53). Thus our findings
that LIMD1 is associated with RISC and the 5′-cap-complex sug-
gests a unique mechanism for tumor suppressive activity. One in
which LIMD1 is intimately involved in the miRNA-mediated ef-
fector silencing function and is distinct from miRNA biogenesis.
Methods
m7GTP-50CAP Pull Down Assay. Cells were suspended in 100 μL CAP buffer.
100 μg protein was incubated with m7GTP Sepharose or control GTP–Sephar-
ose beads (GE Healthcare) when required. 200 μM of m7GpppG analog was
added. The complex was incubated on ice for 15 min in 3 × 200 uL of CAP
buffer. Proteins detected by Western blot analysis.
RNA Interference, Let7 Inhibition and Dual-Luciferase Assay for let-7 siRNA and
miRNA-Mediated Gene Silencing. SMARTpool siRNAs (Dharmacon) were ob-
tained against LIMD1, Ajuba, WTIP, Zyxin, LPP, Trip6, RCK/p54, GW182,
Ago1, Ago2, Lsm1, and a scrambled control. Cells were transfected with
20 nM siRNA using Dharmafect Duo Transfection Reagent (Dharmacon). 2′
OMe inhibitors were transfected at 80 nM 16 h prior to the subsequent trans-
fection of reporter constructs. Subsequent transfection with reporter con-
structs was carried out 48 h post siRNA transfection using 100 ng∕well
PsiCheck-2, PsiCheck-2-Let7asi1 or PsiCheck2-mi3 plasmid DNA or 33.3 ng∕
well pRLSV40L74/siTar2, pRLSV40l78/miTar4, or pRLSV40 with 4.125 ng
PGL3 or 50 ng∕well pMIR-CMV VO or HMGA2 3′UTR and 5 ng pRLSV40
DNA using GeneJuice transfection reagent (Merck Biosciences). After 24 h
cells were lysed in 150 μL passive lysis buffer (Promega) and the luciferase
activities determined with the Promega Dual-luciferase reporter assay system.
For more detailed information, see Methods in SI Text.
Fig. 4. LIMD1, Ajuba, and WTIP are a new family of positive regulators of
miRNA-mediated gene silencing. (A) Phylogenetic analysis based on amino
acid homologies between the six established members of the Zyxin family
of LIM domain containing proteins. This figure shows a clear division into
two subfamilies containing LIMD1, Ajuba, and WTIP (LAW) or Zyxin, LPP,
and TRIP6 (ZLiP). gi_13517496 mouse TRIP6, gi_2558592 human TRIP6,
gi_1537030 human LPP, gi_55154563, mouse LPP, gi_58530845, human zyxin;
gi_6756085 , mouse zyxin; gi_7305237 , mouse LIMD1; gi_7657307 , human
LIMD1; gi_29470380, human Ajuba; gi_31981662 , mouse Ajuba; gi_46402183
, mouseWTIP; gi_89057404 , humanWTIP (B) Ajuba and WTIP colocalize with
LIMD1 to form P-bodies. Vector encoding a LIMD1-Asred fusion protein was
cotransfected into U2OS cells with EGFP fusion proteins of all six family
members. At 48 h posttransfection cells were fixed and visualized via confocal
microscopy. (C) Percentage colocalization efficiency of the indicated EGFP-fu-
sion proteins with LIMD1-Asred fluorescent fusion protein. (D) Comparative
analysis of siRNA-targeted depletion of all six LIM domain family members
together with Ago2 and GW182 and affects on siRNA and miRNA-mediated
repression. U2OS cells were transiently transfected with the indicated siRNA.
At 48 h posttransfection, cells were further transfected with si-Let7 and mi-
Let7 RL/FFL reporter constructs and following a further 24 h, luciferase
activity assayed as described Fig. 3. * indicates p-value ≤0.01
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Fig. 5. LIMD1, Ajuba, and WTIP are recovered specifically with the m7GTP cap structure in association with eIF4E. (A) Extracts derived from cells transfected
with Xpress-tagged LIM-domain proteins were incubated with m7GTP-Sepharose or GTP-Sepharose beads, in the absence (−) and presence (þ) of the m7GpppG
cap analog. Inputs (5%) and bound fractions (40%) were analyzed byWestern blotting using anti-Xpress antibody (LIM family member proteins) or a polyclonal
anti-eIF4E antiserum. (B) m7GTP-Sepharose binding assays were carried out as in panel (A) but with the inclusion of incubation with RNase A where indicated.
(C) GST-VO, GST-Δ472–676, GST-LIMD1, or GST-eIF4E proteins were incubated with U2OS and HEK 293 cell extracts. The GST-tagged proteins were recovered on
Glutathione-Sepharose and the recovery of the indicated endogenous proteins determined by Western blotting. (D) LIMD1 influences the level of Ago2 that
immunoprecipitates with eIF4E. Equal amounts Xpress-tagged LIMD1, Xpress-VO, HA-AGO2, EYFP-eIF4E, or EYFP-VO were transfected into U2OS cells in the
combinations shown. EYFP-tagged proteins were recovered by IP and the association with the indicated proteins determined by Western blotting; the Xpress
vector served as a negative control.
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